Higher Naloxone Doses Narrowly Favored By FDA Panel
Executive Summary
Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.
You may also be interested in...
Will Primatene Mist Inventory Ever Leave The Warehouse?
Amphastar has inventory for the emergency asthma product but is frustrated by the recent second complete response letter from US FDA seeking additional information. Human factors issued figured into CRLs for both Primatene Mist and intranasal naloxone.
Will Primatene Mist Inventory Ever Leave The Warehouse?
Amphastar has inventory for the emergency asthma product but is frustrated by the recent second complete response letter from US FDA seeking additional information. Human factors issued figured into CRLs for both Primatene Mist and intranasal naloxone.
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.